Healing Reimagined
Immunicom’s Immunopheresis® is designed to empower
patients to best live their lives while receiving revolutionary
cancer treatment.This unique immunotherapy is intended
to meaningfully improve patients’ quality of life and
avoid typical side-effects.
LATEST MILESTONE
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
A transformative immunotherapy
Immunicom creates novel immunotherapies designed to treat a variety of diseases using Immunicom’s breakthrough Immunopheresis® technology platform.
The breakthrough Immunopheresis approach uses a therapeutic device that works outside of the body and is designed to treat cancer, inflammatory, renal, and autoimmune diseases by removing barriers from the blood that block the immune system from doing its job.
Our Recognition
Designed to treat
multiple diseases
multiple diseases
Worldwide clinical trials are underway at leading hospitals to evaluate Immunopheresis in several cancer types, both as a singular therapy and in combination with other treatments.
Latest News
June 14, 2022
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
June 2, 2022
Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis® LW-02 Column Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer
June 2, 2022
ASCO Annual Meeting 2022
April 28, 2022
Immunicom Presents New Data at AACR 2022 of LW-02 Cartridge Immunopheresis® Therapy from Ongoing mTNBC Clinical Trial in Chemo-Refractory Patients
Our Mission
To improve the quality of life for patients
in a meaningful way and expedite their
path to a healthy future.
Get in touch today
Let’s talk about what we can achieve together
Learn more about
our team
our team